WallStreetZenWallStreetZen

NASDAQ: NAGE
Niagen Bioscience Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Niagen Bioscience earnings were $17.4M for the trailing 12 months ending Dec 31, 2025, with 100% growth year over year. The latest NAGE earnings report on Dec 31, 2025 announced Q4 2025 earnings of $4.1M, down 9.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NAGE reported annual earnings of $17.4M, with 103.3% growth. The next NAGE earnings date is May 13, 2026.

NAGE past earnings growth

How has NAGE's earnings growth performed historically?

Company
100%
Industry
82.95%
Market
86.97%
NAGE's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NAGE's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NAGE's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NAGE earnings history

Current Revenue
$129.4M
Current Earnings
$17.4M
Current Profit Margin
13.4%

NAGE Return on Equity

Current Company
26.1%
Current Industry
-30.5%
Current Market
28.9%
NAGE's Return on Equity (26.1%)... subscribe to Premium to read more.
High Return on Equity Performance

NAGE Return on Assets

Current Company
18.4%
Current Industry
-9.2%
NAGE is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NAGE announces earnings.

NAGE Return on Capital Employed

Current Company
21.03%
Current Industry
-3.2%
NAGE has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NAGE vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NAGE$19.64M$17.38M+100.00%$0.22
CLYM-$59.55M-$59.85MN/A-$0.88
SRZN-$239.69M-$242.03MN/A-$32.37
PALI-$16.68M-$16.78MN/A-$0.30
EPRX-$38.35M-$38.61MN/A-$1.03
View Top Biotech Stocks

NAGE earnings dates

Next earnings date
May 13, 2026

Niagen Bioscience Earnings Reports & History FAQ

What were Niagen Bioscience's earnings last quarter?

On NAGE's earnings call on Invalid Date, Niagen Bioscience (NASDAQ: NAGE) reported Q4 2025 earnings per share (EPS) of $0.05, up 44.44% year over year. Total NAGE earnings for the quarter were $4.13 million. In the same quarter last year, Niagen Bioscience's earnings per share (EPS) was $0.09.

If you're new to stock investing, here's how to buy Niagen Bioscience stock.

When does Niagen Bioscience report earnings?

The next NAGE earnings call is Invalid Date. Add NAGE to your watchlist to be reminded of Niagen Bioscience's next earnings date.

Is Niagen Bioscience profitable or losing money?

As of the last Niagen Bioscience earnings report, Niagen Bioscience is currently profitable. Niagen Bioscience's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $17.38 million, a 103.3% increase year over year.

What was NAGE's earnings growth in the past year?

As of Niagen Bioscience's earnings date in Invalid Date, Niagen Bioscience's earnings has grown 100% year over year. This is 17.05 percentage points higher than the US Biotechnology industry earnings growth rate of 82.95%. NAGE earnings in the past year totalled $17.38 million.

What are Niagen Bioscience's earnings expectations?

The current EPS estimate for Niagen Bioscience's earnings report in Invalid Date is $0.05.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.